Nanoparticle Delivery of Cisplatin and Aspirin to Treat Cancer
- *Abstract
-
Application
· Prodrug, Platin-A, that is comprised of atherapeutic combination of cisplatin and aspirin for treatment of cancer,including castration-resistant prostate cancer
· Demonstrated excellent anti-cancer andanti-inflammatory properties in prostate cancer cells, better that thecombination of free cisplatin and aspirin
ProblemsAddressed (benefits/advantages)
· Designed to mitigate typical toxicity issuesassociated with cisplatin
· Limits ototoxicity, nephrotoxicity and somelevels of neurotoxicity while being as effective as cisplatin
· Generates powerful general anti-inflammatoryeffects as well as demonstrating neuroprotective properties
· Reduction of adverse side effects can drivesignificant adoption by patients/physicians while saving payers significantcosts
· Cisplatin is first-line therapy for many typesof cancer, making this discovery especially important for patient populationsthat may have sensitivity to cisplatin
· Given that both components of the prodrug arewell known, this may speed the IND toxicity, scale-up manufacturing andregulatory processes
TechnologySummary
Chronic inflammationplays an important role in approximately 20% of human cancers. Prostate cancer (PCa) is the most frequentlydiagnosed cancer and the second leading cause of cancer death in men in theUnited States. Patients with PCainevitably progress to hormone-independent disease. PCa that progresses in the presence ofandrogen blockade is defined as Castration-Resistant Prostate Cancer(CRPC). A complex immune-mediatedprocess and inflammation play crucial roles in PCa progression in the castratesetting and cancer-associated inflammation functionally plays an important rolein the formation of metastasis.
Cisplatinis currently one of the most effective anticancer drugs available for treatinga variety of solid tumors. Nonsteroidalanti-inflammatory drugs (NSAIDs) such as aspirin can be an attractive additiveto chemotherapeutic approaches for PCa due to their ostensive potential in cancerchemoprevention. Because the use ofcisplatin is limited due to its side effects such as nephrotoxicity andototoxicity, addition of an NSAID to a cisplatin therapy could be an attractivestrategy to manage highly aggressive PCa. To that end, Dr. Shanta Dhar has developed Platin-A, a Pt(IV) prodrug thatcan be converted to active forms of both cisplatin and aspirin to overcome theabove-mentioned challenges.
Inventors
· Shanta Dhar, PhD
Dr. Dhar’s research interests lie at the interface ofchemistry and biology with particular emphasis on nanocarrier-mediatedintracellular delivery of payloads for potential applications in variousdiseases.
· Rakesh Pathak, Post-doctoral Fellow
· Sean Marrache
· Joshua Choi
TechnologyDevelopment and IP Status
· Patentpending in US, Europe and Japan and Canada (PCT Publication WO 2015/089389)
· Demonstratedto be efficacious, anti-inflammatory, oto-protective, nephron-protective andneuroprotective in multiple animal species
- *IP Issue Date
- None
- *IP Type
- Utility
- 國家
- Not Applicable (PCT App)
- 申請號碼
- WO 2015/089389
- 國家/地區
- 美國
